Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Neurology

RSS  

Articles

  • Human Insulin Inhalation Powder (Afrezza®)

    A second inhalation rapid human insulin has been approved by the FDA. The first inhaled insulin (Exubera) was approved in 2006 and was withdrawn from the market by Pfizer due to low acceptance and poor sales after about 13 months on the market
  • Should the Physician Go Where the Sun Does Not?

    In a meta-analysis of multiple prospective cohort studies, the lowest vitamin D metabolite (25-hydroxyvitamin D) quintile was associated with increased all-cause mortality, cardiovascular mortality, and cancer mortality.
  • Clinical Briefs

  • Does Beef Get a Bad Rap?

    Contrary to prevailing opinion, eating lean beef may not be bad and perhaps might even favorably affect systolic blood pressure and vascular constriction.
  • Does Gluten Cause Health Problems in Patients Without Celiac Disease?

    Gluten is a protein complex that may be inflammatory to humans and is increasingly recognized as a possible cause of numerous health problems such as irritable bowel syndrome, fibromyalgia, skin conditions, allergies, autoimmune arthritis, and neurodegenerative conditions.
  • Insulin Pump Outperforms Multiple Injections in Type 2 Diabetes

    Sometimes despite best efforts on the part of the clinician and the type 2 diabetes patient, A1c goals are not met. Although in some circumstances the underlying limitation to goal attainment is readily discernible (hypoglycemic episodes, non-compliance, medication misadministration, excessive weight gain, other adverse effects), it is not always so clear.
  • Chest Pain and an Anterior ‘Culprit’

    The ECG in the Figure was obtained from a patient with new-onset chest pain. What is the likely culprit artery? Is this patient a good candidate for acute reperfusion?
  • Ledipasvir and Sofosbuvir Tablets (Harvoni ® )

    The first fixed-dose combination drug product has been approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. The combination contains a previously approved HCV nucleotide analog NS5B polymerase inhibitor, sofosbuvir (SOF), and a NS5A inhibitor, ledipasvir (LDV). This represents the first treatment option for HCV genotype 1 that does not require ribavirin or interferon.
  • Who Is Shopping for You?

    In a study of young adults, attempted physician deception to obtain a pharmaceutical drug was found to exist in a limited manner along with general characteristics of those patients who may divert medications.
  • Medical Treatment Is Effective, ­But Only if It is Used

    In this randomized controlled trial, those sleep apnea patients who received a brief (< 1 hour, total) motivational education program had substantially better continuous positive airway pressure adherence in a short-term follow-up.